Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Dario Demonstrates Improved Workplace Function and Productivity Outcomes Through Digital Behavioral Health Program: Real-World Study Published in JMIR Formative Research

Findings highlight the role of continuous behavioral support in improving focus, productivity and day-to-day functioning – key priorities for employers and health plans Statistically significant improvements in workplace functioning highlight the potential economic value of Dario's digital health solutions for payers NEW YORK, April 20, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in JMIR Formative Research demonstrating meaningful improvements in workplace functioning among participants using Dario's digital behavioral health program. The study, titled Enhancing Workplace Outcomes Through Digital Behavioral Health Programs: Retrospective Real–World Study , demonstrated statistically significant improvements in workplace functioning among users of Dario's behavioral health solutions.

Dario Appoints Veteran Healthcare Executive John R. Palumbo to Board of Directors to Support Accelerated Commercial Scaling

Mr. Palumbo's deep relationships across health systems, payers and healthcare's senior executive community expected to accelerate Dario's commercial partnerships and position the Company to realize its full strategic value NEW YORK, April 13, 2026 /PRNewswire/ --  DarioHealth Corp. (NASDAQ: DRIO) (the "Company" or "Dario"), a leader in global digital health, today announced the appointment of John R. Palumbo to its Board of Directors.

DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 2025 2025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $ 12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectory GAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-GAAP gross margins have sustained at 80% for 2 years on the core B2B2C business Fourth quarter 2025 delivered the lowest operating expense run-rate on both a GAAP and Non-GAAP basis since Twill's acquisition, reducing Non-GAAP operating expenses by 28% year-over-year, from $12.4 million to $9.0 million, leading to continued improvements in operating loss for the fourth quarter and full year Pipeline of commercial opportunities grew to $122 million as of December 31 2025, based on 200+ opportunities that are B2B2C  Increased demand for Dario's musculoskeletal ("MSK") product in the B2C market, with 36% growth in the fourth quarter of 2025 and continued expansion expected in international markets Dario will host an investor conference call and webcast at 8:30 a.m. ET today NEW YORK, March 19, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced its financial results for the fourth quarter and full-year 2025, along with strategic and commercial updates.

Dario Demonstrates Clinically Meaningful Blood Glucose Improvements and Personalized Glycemic Trajectories Across 22,000+ Users: Machine Learning Study Findings Published in Frontiers in Digital Health

Findings reinforce that engagement data provide clinical signals directly impacting ROI Analysis further reveals specific frequency of measurements that drive clinical outcomes and bend the cost curve NEW YORK, March 10, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced the publication of new peer-reviewed research in Frontiers in Digital Health demonstrating substantial and sustained blood glucose improvements among users of the Dario platform.  The observational study, titled " Machine learning and engagement insights for personalized blood glucose management ," analyzed real-world data from 22,414 adults with type 2 diabetes and baseline blood glucose levels in the high-risk range.